These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34230149)

  • 1. Lactate Dehydrogenase Is a Useful Marker for Predicting the Efficacy of Bevacizumab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer.
    Shibutani M; Maeda K; Kashiwagi S; Nagahara H; Fukuoka T; Iseki Y; Wang EN; Okazaki Y; Hirakawa K; Ohira M
    Anticancer Res; 2021 Jul; 41(7):3535-3542. PubMed ID: 34230149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
    Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
    Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
    Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
    PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
    Marmorino F; Salvatore L; Barbara C; Allegrini G; Antonuzzo L; Masi G; Loupakis F; Borelli B; Chiara S; Banzi MC; Miraglio E; Amoroso D; Dargenio F; Bonetti A; Martignetti A; Paris M; Tomcikova D; Boni L; Falcone A; Cremolini C
    Br J Cancer; 2017 Jan; 116(3):318-323. PubMed ID: 28081548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
    Cetin B; Kaplan MA; Berk V; Ozturk SC; Benekli M; Isıkdogan A; Ozkan M; Coskun U; Buyukberber S
    Asian Pac J Cancer Prev; 2012; 13(3):1059-63. PubMed ID: 22631638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
    Giampieri R; Puzzoni M; Daniele B; Ferrari D; Lonardi S; Zaniboni A; Cavanna L; Rosati G; Pella N; Zampino MG; Sozzi P; Germano D; Zagonel V; Codecà C; Libertini M; Labianca R; Cascinu S; ; Scartozzi M
    Br J Cancer; 2017 Oct; 117(8):1099-1104. PubMed ID: 28926529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
    Bar J; Spencer S; Morgan S; Brooks L; Cunningham D; Robertson J; Jürgensmeier JM; Goss GD
    Clin Colorectal Cancer; 2014 Mar; 13(1):46-53. PubMed ID: 24355210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
    Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
    BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
    Kubicka S; Greil R; André T; Bennouna J; Sastre J; Van Cutsem E; von Moos R; Osterlund P; Reyes-Rivera I; Müller T; Makrutzki M; Arnold D;
    Ann Oncol; 2013 Sep; 24(9):2342-9. PubMed ID: 23852309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
    Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.